ArticleScience progress
The association between acute kidney injury and Polymyxin B treatment: A retrospective cohort study.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Eravacycline monotherapy and combination therapy against KPC-2- and NDM-1-co- producingFrontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PurposeThis retrospective study aimed to analyse the impact of polymyxin B (PMB) on nephrotoxicity parameters and identify associated variables.Patients and methodsThe study, which was conducted at a tertiary general hospital in China, included 84 patients over the age of 18 who had received PMB for a period of more than 48 h. Patients were divided into two groups based on the presence or absence of acute kidney injury (AKI) according to KDIGO standards. The identification of risk factors for PMB-associated AKI was facilitated by data collection and multivariate logistic regression analysis.ResultsThe majority of patients were male, with a median age of 80 years (interquartile range (IQR): 68.5, 87.0) and a median weight of 60.0 kg (IQR: 50.0, 65.0). PMB was administered with a median loading dose of 1.73 mg/kg (IQR: 1.67, 1.82) and a median daily maintenance dose of 1.82 mg/kg (IQR: 1.67, 2.22) over a median treatment duration of 7.75 days (IQR: 5.00, 10.38). The development of AKI was observed in 36 patients (42.9%), with a median time to onset of 5 days (IQR: 3, 6). In the cohort of patients who developed AKI, 11 (30.6%) patients discontinued PMB therapy, while 8 (16.7%) patients required renal replacement therapy (RRT). The study revealed that concurrent chronic kidney disease (CKD) (odds ratio (OR) = 5.47, 95% confidence interval (CI) 1.52-19.64,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.